ParkourSC, a San Jose, California company that sells AI software for life sciences and healthcare supply chains, announced on October 14, 2026 that it had acquired Quartic, a fellow San Jose company whose AI applications are used in regulated batch manufacturing. Terms were not disclosed.
Quartic will operate as a ParkourSC company. The combined business plans to give pharmaceutical, biotech and contract manufacturing customers one platform that follows a product from the batch where it was made through clinical supply, commercial distribution and the point of care.
Quartic co-founder and chief executive Rajiv Anand is quoted in the announcement. ParkourSC did not say whether Quartic's team or brand would change.
What Quartic built
Quartic was founded in 2017 and is headquartered on East Gish Road in San Jose, according to CB Insights. It sells a decision intelligence platform for manufacturing operations, combining an industrial data operations layer with AI applications. Biomanufacturers use it to monitor and investigate deviations, run continuous process verification and speed up batch release, all within the GxP rules that govern drug production.
The two companies already shared customers. They cite results including fit-for-use disposition decisions cut from three days to one minute and batch yields in biologics manufacturing improved by 15% to 20%.
“The most important facts about a batch are established when it is made, but they are needed long after it leaves the plant.”
Why ParkourSC is buying
ParkourSC started in clinical trial supply and has since moved into manufacturing, commercial distribution and healthcare. It argues that the record of how a batch was made usually lives in factory systems, while the record of what happened to it afterwards lives in logistics systems, so teams have to rebuild a batch's history when something goes wrong downstream.
By joining the two data sets, ParkourSC says its platform can predict which batches, lots and shipments are at risk and suggest a response, such as adjusting a process, rerouting a shipment, prioritising inventory or speeding up release. Deviations, verification, release, temperature excursions, disposition decisions and regulatory paperwork would sit in one place, above the manufacturing, laboratory, quality and logistics systems customers already run.
ParkourSC president and chief executive Mahesh Veerina said life sciences companies had never had a connected view of a product from its first batch to commercial distribution. The company says the deal makes it the only vendor covering all four main stages of the life sciences value chain, and doubles its addressable market.
ParkourSC describes itself as a vertical AI platform for regulated life sciences and healthcare supply chains, where a wrong decision can cost product, compliance and patient safety. It serves pharmaceutical, biotech and contract manufacturing organisations, distributors and health systems, and says it keeps one continuous product quality record from batch to point of care.
The funding and the backers
Quartic was a small venture-backed company. CB Insights says it raised about $5 million over four rounds, while Dealroom puts its total at $12 million. CB Insights lists its investors as ParkourSC, the consulting firm ZS, Celesta Capital and the investor Michael Marks.
Marks, founding managing partner at Celesta Capital, also sits on ParkourSC's board. He said the industry had paid a steep price in lost product, wasted time and delayed therapies because no one had a complete view of a product across its lifecycle, a problem he said he knew from years of running global supply chains. Dealroom lists ParkourSC itself as having raised $26 million.
What happens to customers
ParkourSC said customers and their partners would not need to replace existing manufacturing execution, laboratory, quality, historian or logistics systems, because the combined platform sits on top of them. It also said process knowledge built up in clinical batches should carry forward into scale-up and technology transfer, shortening the path to commercial supply.
ParkourSC also says that when a temperature excursion or a quality question arises after a batch leaves the plant, disposition can start from the manufacturing evidence rather than from a new investigation. Batches released close to the edge of their specification can be protected before a disruption occurs, because the platform knows how much stability margin they carried out of the factory.
